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Abstract Osteoporosis-pseudoglioma syndrome (OPPG) is a
rare autosomal recessive syndrome characterized by juvenile-
onset osteoporosis and ocular abnormalities due to a low-
density lipoprotein receptor-related protein 5 (LRP5) gene
mutation. Treatment with bisphosphonates, particularly with
pamidronate and risedronate, has been reported to be of some
efficacy in this condition. We report on a patient with OPPG
due to an LRP5 gene mutation, who showed an encouraging
response after a 36-month period of neridronate therapy. We
report a case of a patient treated with bisphosphonates.
Bisphosphonates should be administered in OPPG patients
as a first-line therapy during early childhood.
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Introduction
Osteoporosis-pseudoglioma syndrome (OPPG) is a rare
autosomal recessive disorder characterized by severe
early-onset osteoporosis and blindness [1–4] Typical
OPPG manifestations include fractures and congenital
blindness due to persistence of the fetal fibrovascular
ocular system and failure of retinal development. The
phenotype is variable even among siblings [3].
Osteoporosis usually manifests in early childhood with
recurrent long bone fractures, vertebral compression
fractures and, reduced bone mineral density (BMD).
More severely affected patients may have muscle weak-
ness, bowing of the long bones, and severe spinal defor-
mities [3–5]. The ocular phenotype ranges from vascu-
larization abnormalities from congenital phthisis bulbi to
milder vitreoretinal changes [1–3]. Mental development
is usually normal, but almost 25% of patients show cog-
nitive impairment [1]. OPPG syndrome is caused by ho-
mozygous mutations in the low-density lipoprotein
(LDL) receptor-related protein 5 (LRP5) gene on chro-
mosome 11q13.4 [2, 6].
Based on a few published case reports, treatment
with bisphosphonates improves BMD in patients with
OPPG syndrome [7–9].
The main effect of pharmacologically act ive
bisphosphonates is to reduce bone turnover decreasing
bone resorption. The molecular mechanism has been
partially revealed. It was found that nitrogen-containing
bisphosphonates prevent osteoclast function by
inhibiting the mevalonate pathway, which is responsible
for cholesterol and isoprenoid lipid production [10].
Neridronate is an amino-bisphosphonate that is structur-
ally similar to alendronate and pamidronate. It only dif-
fers in the number of side-chain methyl groups and has
been investigated in Paget bone disease [11] and osteo-
genesis imperfecta [12, 13].
We report the case of a patient with OPPG and a novel
LRP5 mutation who received neridronate treatment for a 36-
month period. We show that neridronate therapy improves the
lumbar spine bone mineral density Z-score, bone turnover
markers, bone pain, and quality of life.
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Case report
A 16-year-old Tunisian boy presented with a suspected diag-
nosis of osteogenesis imperfecta because of limb, femur, radi-
us and ulnar deformities, spinal compression fractures, re-
duced bone mineral density, and a COL1A1 gene
heterozygotic mutation. His parents were first cousins, who
were also sons of consanguineous parents, and were reported
to have the same condition. Eleven additional siblings were
said to be unaffected. No additional information about other
family members, or, data on the neonatal period, were avail-
able. Psychomotor development was normal. The patient was
completely blind, and his visual problems were noted at
10 months of age. At 6 years of age, left tibial bowing was
noted, and right lower limb and spinal deformities, such as
marked kyphosis, subsequently developed.
At the time of our first evaluation, the patient did not show
limb fractures. Psychomotor development was normal. He
had short stature (< 3rd percentile). Ligament laxity was evi-
dent in the lower limbs. The pupils were not reactive to light.
The patient could stand unsupported, but he could walk only
with support because of visual problems.
The ophthalmologic evaluation revealed bilateral cataracts,
right microphthalmia, left retinal calcifications, and visual
evoked potentials were absent. Abdominal and heart ultra-
sounds did not detect anomalies. The auditory brainstem re-
sponse was in the normal range. Skeletal radiographies re-
vealed generalized osteoporosis, scoliosis, dorsal kyphosis,
and bowing and deformation of the lower limbs’ long bones
with a Bserpentine^ left fibula (Fig. 1). Spinal X-rays revealed
severe dorsal vertebral fractures (Fig. 1) but only a mild re-
duction of the body height in the lumbar tract. Lumbar spine
densitometry, performed by DXA (Hologic Discovery
Densitometer 4500), detected a severely reduced bone
mass (Table 1).
On the basis of clinical and instrumental findings, LRP5
gene analysis was performed and revealed a deletion
involving exon 4 and part of introns 3 and 4, as previously
described [14].
After a baseline evaluation of bone and mineral metabo-
lism (Table 1), when the patient was 16 years old, intravenous
treatment with neridronate was started in a single administra-
tion of 2 mg/kg and repeated every 3 months for a total period
of 3 years. We also found a vitamin D deficiency [25(OH)D:
9.5 ng/mL], and we started cholecalciferol and calcium ad-
ministration at a daily dose of 800 UI and 1000 mg, respec-
tively. The efficacy of treatment was established by assessing
the patient’s bone pain, growth parameters, bone turnover
markers, spine X-rays, and lumbar spine bone densitometry
(Table 1). The numerical rating scale (NRS), a subjective psy-
chometric response scale based on a numerical gradient from
0 (no pain) to 10 (Bworst possible pain^), showed a significant
reduction of bone pain (5 vs 9 initial evaluation) after 6months
of neridronate treatment; no pain was reported in the follow-
ing visits. Serum osteocalcin (BGP), a bone formation marker,
peaked at 12 months and remained higher compared with the
baseline value. Collagen type 1 C-telopeptide (CTX) and
bone-alkaline phosphatase (BALP), which are respectively
bone resorption and formation markers, showed a significant
reduction after 12 months of treatment and an additional slight
reduction after 24 and 36 months, compared with the baseline
levels. There were no changes in the calcium, phosphorus, or
PTH serum levels. Before treatment, 25(OH)D was insuffi-
cient, but after a 12-month period of cholecalciferol adminis-
tration at a daily dose of 800 UI, it became normal and
remained within the normal range after 24 and 36 months of
evaluation. A spinal X-ray was repeated at the end of the
treatment and no new fractures were detected on radiographies
during the 36-month period of treatment. Regarding lumbar
spine mineral bone densitometry, the bone mineral content
(BMC) and bone mineral density (BMD) were substantially
below the normal values at presentation. During treatment, a
substantial improvement in BMC and BMD was observed.
The BMC had an increase of 35.5% by 1 year and from
Fig. 1 Radiographs of the spine
revealed severe dorsal vertebral
fractures (1a), and deformation of
the long bones as Bserpentine^
left fibula (1b), before neridronate
treatment
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67.7 to 69.4% by 36 months. The BMD Z-score was − 6.1 at
presentation, − 3.8 after 1 year, − 3.6 after 2 years, and − 3.3
after 3 years (p < 0.001 paired t test) (Table 1). According to
the normal values given by the manufacturers, we would have
been expected a BMD increase of 45.9% during the entire 36-
month period.
Informed consent was obtained from the subject described
in the study.
Discussion
The patient reported herein was diagnosed with a very rare
form of juvenile-onset severe osteoporosis and blindness
known as OPPG. The genetic data have been previously
discussed [14].
To date, approximately 70 patients have been reported in
literature. Bone fractures, vertebral compression fractures,
BMD reductions, and ocular anomalies due to abnormal vas-
cularization include retrolental masses, phthisis bulbi,
microphthalmia, microcornea, clouding of the cornea and
lens, intraocular hemorrhage, and retinal detachment are pres-
ent in early childhood [7–9]. Alonso N et al. described the first
case of atypical subtrochanteric femoral fracture in an OPPG
patient with two novel LRP5 mutations [15].
Homozygous or compound heterozygous loss-of-function
mutations of the LRP5 gene cause OPPG [2]. LRP5 acts as a
transmembrane coreceptor in the Wnt signaling pathway,
which is involved in the regulation of osteoblast growth and
differentiation. LRP5 acts in gut cells, not in osteoblasts, to
control bone formation via a Wnt-independent pathway and
identifies a new hormone, serotonin, and a novel endocrine
axis regulating bone mass, with important therapeutic impli-
cations [16]. LRP5 anomalies are known to cause recessive
familiar exudative vitro-retinopathy [17] and an autosomal
dominant syndrome with high bone density, a wide and deep
mandible, and torus palatinus.
Few open-label studies describe therapeutic options in
OPPG patients. In particular, the efficacy of bisphosphonates
has been reported in 12 patients overall [7, 9]. Zacharin and
Cundy first reported in 2000 the effect of a 2-year administra-
tion of bisphosphonate (pamidronate in two cases and
clodronate in one case). The authors reported clinical im-
provement in terms of (a) reduction of bone pain within the
first month of treatment, (b) lower morbidity especially after
6 months, (c) no detection of new fractures on radiography
during the entire 2-year period of treatment, and (d) improve-
ments in vertebral height and end plate remodeling. Some
authors assert that bone resorption markers showed an initial
suppression during the first 3 to 6 months of treatment in all 3
subjects evaluated, but the levels subsequently increased. The
same pattern was observed for osteocalcin but not for alkaline
phosphatase [8].
Similar results using pamidronate were shown by Di Iorgi
N [18] and Bayram F et al. in 2006 [19].
Subsequently, Streeten EA and colleagues [7] described
improvement in the BMD Z-score in OPPG patients after
bisphosphonates administration and with the osteoanabolic
drug teriparatide after stopping the bisphosphonates. They
reported a beneficial response to bisphosphonates in 4 patients
and the lack of a definitive response to teriparatide in 1 patient.
This finding suggested the initiation of bisphosphonates treat-
ment in OPPG patients. Barros ER et al. reported a 3-year
follow-up of pamidronate therapy in two brothers with
OPPG. He observed an increased BMD and decreased frac-
ture rate [20].
In 2011, Arantes HP. et al. described a patient treated for
2 years with teriparatide [21]. Over 2 years of treatment, the
Table 1 Calcium metabolism
parameters, bone turnover
markers, and bone mineral
density during neridronate
treatment
T0 1 year 2 years 3 years p
Serum calcium (adjusted for serum
albumin levels) (mg/dL) (n.v. 8.40–10.0)
9.1 8.8 8.8 8.8 n.s.a
Serum phosphate (mg/dL) (n.v. 2.80–4.60) 3.4 3.5 3.3 3.4 n.s.a
Intact PTH (pg/mL) (n.v. 10.6–54) 46.9 43.4 44.6 43.7 n.s.a
CTX (ng/mL) (n.v. 0.11–0.75) 2.1 1.0 1.1 0.5 0.001a
25-OH vit D (ng/mL) (n.v. > 32) 9.5 28 32 32 0.01a
BALP (U/L) (n.v. 15.0–41.3) 190 73.7 65.2 63.1 0.01a
Serum osteocalcin (ng/mL) (n.v. 24.0–70.0) 21 74.8 76.43 78.2 0.01a
Lumbar spine area (cm2) 39.9 44.7 48.8 43.8 0.01a
Lumbar spine BMC (g) 17.5 23.8 29.4 29.7 0.01a
Lumbar spine BMD (g/cm2) 0.44 0.53 0.60 0.67 0.001a
Lumbar spine BMD (Z-score) − 6.1 − 3.8 − 3.6 − 3.3 0.001a
Significance p < 0.05. p value represents the significance of the difference of results at the four time points
determined using analysis of variance
a Significant difference to result at 3 years vs T0 (paired t test)
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BMD markedly increased in the lumbar spine and in the right
total hip. The CTx level reached a peak by 3 months and
slowly returned to the baseline level by 24 months.
Bisphosphonates primarily work by inhibiting osteoclastic
bone resorption. In our patient, this occurrence was reflected
by an early reduction in bone resorption markers. Whether
bisphosphonates influence the basic defect in OPPG is not
clear at present but an important component of their efficacy
may be their action to reduce bone pain and bone loss due to
immobility. The neridronate effects on spinal bone density
observed in our patients were similar to those described for
other bisphosphonates, administered either orally or intrave-
nously, in different forms of childhood osteoporosis [12, 13].
In conclusion, our results in terms of increased bone mineral
density, pain reduction, and better quality of life suggest that
ner idronate is an al ternat ive t rea tment to other
bisphosphonates already described.
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